Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06866236
PHASE2/PHASE3

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Sponsor: Ebima Clifford Okundaye

View on ClinicalTrials.gov

Summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Official title: Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

3000

Start Date

2025-10

Completion Date

2027-07

Last Updated

2025-09-08

Healthy Volunteers

No

Interventions

DRUG

QRX-3

capsule

Locations (1)

Neukidney Inc

Pasedena, Texas, United States